Literature DB >> 7940403

Embryotoxic effects of thalidomide derivatives in the non-human primate callithrix jacchus. IV. Teratogenicity of micrograms/kg doses of the EM12 enantiomers.

W Heger1, H J Schmahl, S Klug, A Felies, H Nau, H J Merker, D Neubert.   

Abstract

The dose-response of the teratogenic potency of the thalidomide (Thd) derivative EM12 was evaluated in the common marmoset (Callithrix jacchus). The smallest daily dose found to be effective was 30 micrograms EM12/kg body wt. This is the lowest dose of a Thd derivative ever reported to induce severe skeletal abnormalities. Ten micrograms EM12/kg body wt may be considered the no-observed-adverse-effect-level (NOAEL) under the experimental conditions chosen. The teratogenic potencies of the two EM12 enantiomers were tested at 100 micrograms/kg body wt, the dose which just induces an almost 100% effect in the case of the racemate. The S(-)-EM12 was found to induce typical severe limb abnormalities such as amelia, phocomelia, and radius aplasia, and none of the exposed fetuses were devoid of skeletal defects. In contrast, only few and minor skeletal defects were observed after application of the R(+) enantiomer. Although a pronounced teratogenic potency of the R(+)-EM12 can now largely be excluded, these low-dose studies are not sufficient to completely rule out any teratogenic potential of this enantiomer, since racemisation to small amounts of the S(-) form may occur in vivo. Further studies with Thd derivatives which are unable to racemise are necessary to prove the assumed complete ineffectiveness of the R(+) enantiomers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7940403     DOI: 10.1002/tcm.1770140303

Source DB:  PubMed          Journal:  Teratog Carcinog Mutagen        ISSN: 0270-3211


  7 in total

Review 1.  Thalidomide-type teratogenicity: structure-activity relationships for congeners.

Authors:  R L Smith; S C Mitchell
Journal:  Toxicol Res (Camb)       Date:  2018-09-26       Impact factor: 3.524

Review 2.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

3.  Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.

Authors:  Aneta Doricakova; Dirk Theile; Johanna Weiss; Radim Vrzal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-27       Impact factor: 3.000

4.  Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus. 5. Lack of teratogenic effects of phthalimidophthalmide.

Authors:  S Klug; A Felies; H Stürje; A C Nogueira; R Neubert; E Frankus
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

5.  Structural basis of thalidomide enantiomer binding to cereblon.

Authors:  Tomoyuki Mori; Takumi Ito; Shujie Liu; Hideki Ando; Satoshi Sakamoto; Yuki Yamaguchi; Etsuko Tokunaga; Norio Shibata; Hiroshi Handa; Toshio Hakoshima
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

6.  A Comparative Study of Coupled Preferential Crystallizers for the Efficient Resolution of Conglomerate-Forming Enantiomers.

Authors:  Aniruddha Majumder; Zoltan K Nagy
Journal:  Pharmaceutics       Date:  2017-12-05       Impact factor: 6.321

7.  Overview of the marmoset as a model in nonclinical development of pharmaceutical products.

Authors:  Antonia Orsi; Daryl Rees; Isabella Andreini; Silvana Venturella; Serena Cinelli; Germano Oberto
Journal:  Regul Toxicol Pharmacol       Date:  2010-12-13       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.